TY - JOUR
T1 - An electrochemical biosensor to simultaneously detect VEGF and PSA for early prostate cancer diagnosis based on graphene oxide/ssDNA/PLLA nanoparticles
AU - Pan, Lung Hsuan
AU - Kuo, Shin Hung
AU - Lin, Tzu Yang
AU - Lin, Chih Wen
AU - Fang, Po Yu
AU - Yang, Hung Wei
N1 - Funding Information:
We thank the Ministry of Science and Technology , Chang Gung Memorial Hospital , and the Food Industry Research and Development Institute, Taiwan (R.O.C.), for the financial assistance provided ( MOST103-2320-B-110-004-MY2 , CMRPG3E2041 , CMRPG3B1601 , GERPD2E0031 ). We would also like to thank the Chang Gung Memorial Hospital Microscopy Core Laboratory and National Nano Device Laboratories for their assistance.
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2017/3/15
Y1 - 2017/3/15
N2 - Early diagnosis of prostate cancer (PCa) is critical for the prevention of metastasis and for early treatment; therefore, a simple and accurate device must be developed for this purpose. In this study, we reported a novel fabrication method for producing a dual-modality biosensor that can simultaneously detect vascular endothelial growth factor (VEGF) and prostate-specific antigen (PSA) in human serum for early diagnosis of PCa. This biosensor was constructed by coating graphene oxide/ssDNA (GO-ssDNA) on an Au-electrode for VEGF detection, and incorporated with poly-L-lactide nanoparticles (PLLA NPs) for signal amplification and PSA detection. The results showed that this biosensor has wide liner detection ranges (0.05–100 ng/mL for VEGF and 1–100 ng/mL for PSA), as well as high levels of sensitivity and selectivity (i.e., resisting interference from external factors, such as glucose, ascorbic acid human serum protein, immunoglobulin G, and immunoglobulin M), and demonstrated a high correlation with an enzyme-linked immunosorbent assay for sample detection in patients. Therefore, this biosensor could be utilized for early clinical diagnosis of PCa in the future.
AB - Early diagnosis of prostate cancer (PCa) is critical for the prevention of metastasis and for early treatment; therefore, a simple and accurate device must be developed for this purpose. In this study, we reported a novel fabrication method for producing a dual-modality biosensor that can simultaneously detect vascular endothelial growth factor (VEGF) and prostate-specific antigen (PSA) in human serum for early diagnosis of PCa. This biosensor was constructed by coating graphene oxide/ssDNA (GO-ssDNA) on an Au-electrode for VEGF detection, and incorporated with poly-L-lactide nanoparticles (PLLA NPs) for signal amplification and PSA detection. The results showed that this biosensor has wide liner detection ranges (0.05–100 ng/mL for VEGF and 1–100 ng/mL for PSA), as well as high levels of sensitivity and selectivity (i.e., resisting interference from external factors, such as glucose, ascorbic acid human serum protein, immunoglobulin G, and immunoglobulin M), and demonstrated a high correlation with an enzyme-linked immunosorbent assay for sample detection in patients. Therefore, this biosensor could be utilized for early clinical diagnosis of PCa in the future.
UR - http://www.scopus.com/inward/record.url?scp=84956866223&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956866223&partnerID=8YFLogxK
U2 - 10.1016/j.bios.2016.01.077
DO - 10.1016/j.bios.2016.01.077
M3 - Article
C2 - 26868935
AN - SCOPUS:84956866223
SN - 0956-5663
VL - 89
SP - 598
EP - 605
JO - Biosensors and Bioelectronics
JF - Biosensors and Bioelectronics
ER -
